Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm focused on the development and commercialization of advanced biopharmaceutical products. The company leverages its proprietary technologies and a diverse product pipeline to address critical medical needs, positioning itself strategically to enhance treatment outcomes across multiple therapeutic areas. With a robust commitment to research and development, ZYBT aims to drive significant growth and deliver substantial value to its investors, while maintaining a strong emphasis on quality and innovation within the dynamic biotechnology landscape.
| Revenue (TTM) | $116.36M |
| Gross Profit (TTM) | $23.87M |
| EBITDA | $-44.62M |
| Operating Margin | -77.00% |
| Return on Equity | -25.20% |
| Return on Assets | -9.48% |
| Revenue/Share (TTM) | $2.46 |
| Book Value | $0.92 |
| Price-to-Book | 1.09 |
| Price-to-Sales (TTM) | 0.35 |
| EV/Revenue | 2.54 |
| EV/EBITDA | 17.36 |
| Quarterly Earnings Growth (YoY) | -79.60% |
| Quarterly Revenue Growth (YoY) | -40.90% |
| Shares Outstanding | $47.39M |
| Float | $4.42M |
| % Insiders | 0.00% |
| % Institutions | 1.10% |